Predictive Factors for Return to Work After a First Stroke Treated at Clermont-Ferrand University Hospital in Puy de Dôme Between January 2020 and December 2024 (RTWS2)

September 7, 2026 updated by: University Hospital, Clermont-Ferrand
Stroke is a leading cause of acquired motor disability and the second most common cause of major cognitive impairment worldwide. In France, approximately 150,000 new cases occur annually, with around 31% affecting individuals of working age, making return to work (RTW) a critical public health issue. Beyond the medical burden, stroke has profound socio-economic consequences, including loss of productivity, prolonged sick leave, part-time resumption, and the need for workplace adaptations. While RTW after stroke has been investigated, major gaps remain. No standardized recommendations exist for vocational reintegration, and predictive factors are still debated. Quantitative determinants such as stroke type, severity, functional independence, and occupational characteristics have been identified, but qualitative aspects-including self-efficacy, perceived social burden, employer relationships, and motivation-are poorly documented. Moreover, cognitive deficits are often insufficiently characterized, as screening tools such as MMSE or MoCA lack the sensitivity of comprehensive neuropsychological assessments. The impact of revascularization procedures on RTW and the ability to sustain employment after initial resumption also remain unclear. Importantly, no recent data are available in the Auvergne region, despite evolving labor policies that may influence reintegration trajectories. This observational study therefore aims to identify both quantitative and qualitative predictors of RTW after ischemic or hemorrhagic stroke, describe vocational pathways in a regional cohort, and explore barriers and facilitators to long-term reintegration. Ultimately, the study seeks to provide updated evidence to guide tailored rehabilitation and socio-professional reintegration strategies, supporting sustainable RTW in working-age stroke survivors.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

190

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Clermont-Ferrand, France
        • CHU Clermont-Ferrand, Louise Michel
    • France
      • Cébazat, France, France, 63118
        • Clermont Ferrand University Hospital, Louise Michel site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Stroke management follows a continuum, starting with acute care in neurology and neurosurgery, then progressing to medium- and long-term multidisciplinary rehabilitation in the Physical Medicine and Rehabilitation (PMR) department of Clermont-Ferrand University Hospital. Within this context, return to work is a key objective, supported by the expertise of PMR teams and close collaboration with neurology and neurosurgery. To conduct this study, authorisation to access medical records was granted by the Medical Information Department (DIM), covering patients under 64 years old admitted for ischaemic or haemorrhagic stroke between January 2020 and December 2024. Screening will be performed on hospitalisations in neurology and neurosurgery, and all eligible patients experiencing a first stroke during this period will be invited to participate.

Description

Inclusion Criteria:

  • Patients who have suffered an ischaemic stroke according to ICD-10 (ICD-10 code: I63 (cerebral infarction) I64 (unspecified stroke), I69 (sequelae of cerebrovascular disease) or patients who have had a haemorrhagic stroke according to ICD-10 (ICD-10 code: I60, I61 and I62) between January 2020 and March 2024
  • Patients of working age/under 64 years of age (legal retirement age)
  • Patients with an employment contract at the time of the stroke
  • Patients treated at Clermont-Ferrand University Hospital
  • Post-stroke consultation recorded in the patient's medical file
  • Patients affiliated with the social security system
  • Patients who have not objected to participating in the study

Exclusion Criteria:

  • Patients with a history of ischaemic or haemorrhagic stroke
  • Patients with a history of head trauma with neurological sequelae corresponding to codes S060, S061, S062, S063, S065, S066, S067, S068 and S069
  • Patients who died as a result of stroke
  • Patients unable to respond to telephone questionnaires
  • Patients under guardianship or trusteeship
  • Patients who have suffered a transient ischaemic attack (TIA) (G459 according to ICD 10)
  • Patients who were in early retirement at the time of assessment
  • No information on employment after stroke in the medical file
  • Patients with category 2 or 3 disability prior to stroke due to another condition
  • Patients on sick leave prior to stroke due to another condition
  • Patients receiving RSA income support

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Return to work rate
Time Frame: At inclusion
Percentage of return to work after a first ischaemic or haemorrhagic stroke between January 2020 and December 2024 in patients of working age.
At inclusion
Factors correlated with return to work
Time Frame: At inclusion
Determine the factors associated with return to work (gender)
At inclusion
Factors correlated with return to work
Time Frame: At inclusion
Determine the factors associated with return to work (stroke severity)
At inclusion
Factors correlated with return to work
Time Frame: At inclusion
Determine the factors associated with return to work (stroke type (ischaemic or haemorrhagic)).
At inclusion
Factors correlated with return to work
Time Frame: At inclusion
Determine the factors associated with return to work (independence)
At inclusion
Factors correlated with return to work
Time Frame: At inclusion
Determine the factors associated with return to work (occupation)
At inclusion

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quality of life after stroke
Time Frame: At inclusion
The Short-Form-12 (SF-12) questionnaire is a standardized self-administered questionnaire used to assess health-related quality of life. It comprises 12 questions covering 8 domains: physical activities, physical and mental limitations, pain, perceived general health, vitality, mental health and social relationships. Each item is rated on a 5- or 6-point Likert scale. The responses are used to calculate two scores: a physical composite score (PCS) and a mental composite score (MCS), each ranging from 0 (perceived health status very poor) to 100 (perceived health status optimal).
At inclusion
Anxiety and Depression scale
Time Frame: At inclusion
The Hospital Anxiety and Depression Scale (HADs) questionnaire is a psychometric self-assessment questionnaire consisting of 14 items divided into two subscales (anxiety and depression) of seven items each. Each item is rated on a scale of 0 to 3. A score is given for each subscale, A for anxiety and D for depression. The score can range from 0 (no anxiety and/or depressive disorders) to 21 (proven anxiety and/or depressive disorders of varying severity) for each subscale.
At inclusion
Fatigue Severity Scale
Time Frame: At inclusion
The Fatigue Severity Scale (FSS) questionnaire is a self-assessment tool used to evaluate the severity of fatigue and its impact on daily activities. This questionnaire consists of nine items rated on a seven-point Likert scale, ranging from 1 ('strongly disagree') to 7 ('strongly agree'). The score ranges from 7 (no fatigue in daily activities) to 63 (extreme fatigue in daily activities). A score above 36 indicates that the patient may need to have their fatigue assessed by a healthcare professional.
At inclusion
Predictive score for return-to-work rate
Time Frame: At inclusion
Develop a predictive score for return to work using the predictive factors for return to work identified in the main objective.
At inclusion
Job retention
Time Frame: At inclusion
To study job retention and its association with factors such as stroke severity.
At inclusion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Lise Laclautre, University Hospital, Clermont-Ferrand

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 29, 2025

Primary Completion (Actual)

January 22, 2026

Study Completion (Actual)

January 22, 2026

Study Registration Dates

First Submitted

September 12, 2025

First Submitted That Met QC Criteria

December 2, 2025

First Posted (Actual)

December 4, 2025

Study Record Updates

Last Update Posted (Actual)

September 9, 2026

Last Update Submitted That Met QC Criteria

September 7, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe